SecBot SecBot
PRESS-RELEASE ·Filed Mar 19, 2026

RLMD

Relmada Therapeutics
BULLISH
Impact 8/10
Horizonmonths Processed8mo ago WireGlobeNewswire
Press release · Earnings
Actionable Insight ▲ Bullish

Investors should monitor initiation of the Phase 3 RESCUE program in mid-2026 and initial 3-month NDV-01 data from the 2L BCG-unresponsive study expected by year-end 2026. The combination of strong Phase 2 durability, clean safety profile, and extended funding significantly de-risks near-term development and increases probability of regulatory success.

DirectionBullish
Confidencehigh
Horizonmonths

How the stock moved after the report

BULLISH VIEWSTOCK ABOVE ENTRY AT T+60
Entry
$6.07
T+0 close · Mar 19, 2026 · via day close
Latest settled
+4.94%
T+60 · $6.37
Vs SPY
−9.48%
α at T+60
Horizons
All settled
through T+60
  1. T+0 · Mar 20 $6.07entry
  2. T+1 · 8mo ago −3.46%α −4.56% · $5.86
  3. T+5 · 8mo ago +5.93%α +8.08% · $6.43
  4. T+20 · 7mo ago +21.42%α +12.10% · $7.37
  5. T+60 · 5mo ago +4.94%α −9.48% · $6.37
Loading chart...

How similar events traded

How similar events traded

See how far stocks moved after events like this one.

Subscribe for Full Access

Executive Summary

Relmada Therapeutics reported financial results for 2025 and provided a corporate update highlighting positive 12-month Phase 2 data for NDV-01 in non-muscle invasive bladder cancer (NMIBC), showing a 76% durable complete response rate and favorable safety. The company secured $160 million in PIPE financing in March 2026, boosting its cash runway through 2029 to fund the upcoming Phase 3 RESCUE program. Despite a reduced net loss, the company remains pre-revenue with no near-term earnings inflection.

Key Financial Metrics

EPS
$-1.45
Deal Value
$160.0M

Key Facts

  • NDV-01 Phase 2 data shows 76% complete response (CR) rate at 12 months and 95% CR at any time in high-risk NMIBC; 80% CR at 12 months in BCG-unresponsive patients
  • No Grade ≥3 treatment-related adverse events or treatment discontinuations observed
  • FDA alignment confirmed on two registrational pathways for NDV-01: adjuvant intermediate-risk NMIBC and 2L BCG-unresponsive NMIBC
  • Oversubscribed $160 million PIPE financing completed in March 2026, led by top healthcare investors
  • Cash balance of $93.0 million as of December 31, 2025, now expected to fund operations through 2029 including Phase 3 development
  • Phase 3 RESCUE program initiation expected mid-2026; U.S. IND clearance also anticipated mid-2026
  • Net loss for 2025 was $57.4 million ($1.45/share), improved from $80.0 million ($2.65/share) in 2024

Financial Impact

Cash runway extended to 2029 with $253M total liquidity (existing $93M + $160M PIPE); R&D spend decreased 42% YoY to $26.9M due to completion of prior trials

cashR&D expensenet lossdilution

Risk Factors

  • Phase 3 trial may not replicate Phase 2 efficacy or safety results
  • Regulatory delays or failure to maintain alignment with FDA on trial design
  • Dilution risk from future financings if additional capital is needed beyond 2029

Market Snapshot

Exchange
Nasdaq

Investment Themes

Documents Analyzed

This report is based on 1 press release from GlobeNewswire.

DocumentAccession Number
PRESS-RELEASE Data (Synthetic)press-3259417

Track record

11 reports on RLMD

Performance horizon

The track record builds as more bullish or bearish reports settle.

Filters
  1. Nov 16, 2026today SC 13G/A Bearish 5/10 Entry $3.54 Now $3.61 −1.98% settles Dec 15
  2. Nov 16, 2026today 8-K Neutral 3/10 Entry $4.16 Now $3.61 −13.23% settles Dec 15
  3. Nov 12, 20264d ago 8-K Neutral 4/10 Entry $4.21 Now $3.61 −14.25% settles Dec 14
  4. Sep 11, 20269w ago Insider Cluster Bullish 6/10 Entry $4.52 to $3.39 Now $3.61 −20.13% ▼ −25.00% −26.87% vs SPY
  5. May 13, 202626w ago S-3ASR Bearish 6/10 Entry $7.42 to $6.65 Now $3.61 +51.35% ▲ +10.38% +9.52% vs SPY
  6. May 12, 202626w ago 8-K Neutral 4/10 Entry $7.49 to $6.52 Now $3.61 −51.80% ▼ −12.95% −12.34% vs SPY
  7. Apr 17, 202630w ago DEFA14A Neutral 3/10 Entry $7.37 to $6.34 Now $3.61 −51.02% ▼ −13.98% −18.18% vs SPY
  8. Apr 3, 202632w ago S-3 Neutral 3/10 Entry $6.90 to $7.41 Now $3.61 −47.68% ▲ +7.39% −1.59% vs SPY
  9. Mar 19, 202634w ago Press Release Bullish 8/10 Viewing Entry $6.07 to $7.37 Now $3.61 −40.53% ▲ +21.42% +12.10% vs SPY
  10. Mar 12, 202635w ago Press Release Neutral 3/10 Entry $6.15 to $7.29 Now $3.61 −41.30% ▲ +18.54% +16.56% vs SPY
Showing 10 of 11

US Market Status

Market Closed · Opens in 6h 38m

Subscribe to SecBot

Get Real-Time SEC Filing Intelligence

Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.

Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers
Report published Mar 19, 2026